Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evotec (GB:0IRF)
LSE:0IRF
Holding GB:0IRF?
Track your performance easily
0IRF Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.90 - €21.65
Previous Close€6.39
Volume260.46K
Average Volume (3M)139.32K
Market Cap
€1.12B
Enterprise Value€520.88M
Total Cash (Recent Filing)€604.11M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 06, 2024EPS Estimate
-€0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding176,952,653
10 Day Avg. Volume157,388
30 Day Avg. Volume139,322
Standard Deviation0.13
R-Squared0.06
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.87
Price to Sales (P/S)6.20
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.71Price Target Upside67.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Evotec News
Bulls Say, Bears Say
Bulls Say
DivestmentsEvotec has already started to reduce its footprint and teased additional divestments of non-core assets, reiterating its sustainable yearly savings target of EUR 40m.
Partnership ExtensionThe recently announced extension of the biosimilar partnership with Sandoz is good news for the case.
Revenue SecuritySandoz agreed to develop another two biosimilars with Evotec and has agreed to do commercial manufacturing for the entire biosimilar portfolio, removing a significant element of uncertainty and securing commercial revenues for J.POD 2 for the period after 2030.
Bears Say
Cyberattack ImpactA cyberattack in H1 2023 has resulted in a low comparable base, and while Q2 2024 earnings expectations appear positive, they still fall short of Evotec’s previous EBITDA levels.
Financial GuidanceEvotec has cut its guidance from low double-digit percentage sales growth to sales of EUR 790-820m, significantly below the consensus of EUR 878m.
Operational ChallengesHigher ramp-up costs than expected for more development capacity in connection with the expanded Sandoz partnership are impacting financial performance.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.16% Insiders
14.92% Mutual Funds
6.13% Other Institutional Investors
78.79% Public Companies and
Individual Investors
0IRF FAQ
What was Evotec’s price range in the past 12 months?
Evotec lowest share price was €4.90 and its highest was €21.65 in the past 12 months.
What is Evotec’s market cap?
Currently, no data Available
When is Evotec’s upcoming earnings report date?
Evotec’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Evotec’s earnings last quarter?
Evotec released its earnings results on Aug 14, 2024. The company reported -€0.54 earnings per share for the quarter, missing the consensus estimate of -€0.07 by -€0.47.
Is Evotec overvalued?
According to Wall Street analysts Evotec’s price is currently Undervalued.
Does Evotec pay dividends?
Evotec does not currently pay dividends.
What is Evotec’s EPS estimate?
Evotec’s EPS estimate is -€0.04.
How many shares outstanding does Evotec have?
Evotec has 177,553,390 shares outstanding.
What happened to Evotec’s price movement after its last earnings report?
Evotec reported an EPS of -€0.54 in its last earnings report, missing expectations of -€0.07. Following the earnings report the stock price went up 3.276%.
Which hedge fund is a major shareholder of Evotec?
Currently, no hedge funds are holding shares in GB:0IRF
---
Evotec Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€10.71 (67.55% Upside)
€10.71 (67.55% Upside)
Insider Transactions
Bought Shares
Worth €436.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.39%
12-Months-Change
Fundamentals
Return on Equity
-15.62%
Trailing 12-Months
Asset Growth
-13.14%
Trailing 12-Months
Company Description
Evotec
Evotec SE is a drug discovery partnership company providing drug discovery solutions to pharmaceutical and biotechnology companies, academic institutions as well as foundations and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes and complications of diabetics, pain and inflammation, oncology and infectious diseases. Its business segments are EVT execute and EVT Innovate. The EVT execute provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The majority of the revenue is generated from the EVT execute segment.
---
0IRF Stock 12 Month Forecast
Average Price Target
€10.71
▲(67.55% Upside)
Technical Analysis
Best Analysts Covering 0IRF
1 Year
1 Year Success Rate
12/20 ratings generated profit
1 Year Average Return
+6.37%
reiterated a sell rating last month
Copying Falko Friedrichs's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +6.37% per trade.
---